![Paolo Tarantino on Twitter: "In June 2020, an issue of JCO was published, including the first data of T-DXd in HER2-low MBC & the first review on this entity (https://t.co/peW12yxzPp) 2 years Paolo Tarantino on Twitter: "In June 2020, an issue of JCO was published, including the first data of T-DXd in HER2-low MBC & the first review on this entity (https://t.co/peW12yxzPp) 2 years](https://pbs.twimg.com/media/FRXYbrzXsAABoT6.jpg:large)
Paolo Tarantino on Twitter: "In June 2020, an issue of JCO was published, including the first data of T-DXd in HER2-low MBC & the first review on this entity (https://t.co/peW12yxzPp) 2 years
Scholarly Article or Book Chapter | Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial | ID: x346d625j | Carolina Digital Repository
![Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/dace42da-0f5d-4ff4-9fba-d7d92081b7c6/gr1_lrg.jpg)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
![Extended Hypofractionated Cancer Radiation Therapy Against Aged and Non-aged Breast Carcinomas Patients | European Journal of Clinical Medicine Extended Hypofractionated Cancer Radiation Therapy Against Aged and Non-aged Breast Carcinomas Patients | European Journal of Clinical Medicine](https://www.ej-clinicmed.org/public/journals/1/article_59_cover_en_US.jpg)
Extended Hypofractionated Cancer Radiation Therapy Against Aged and Non-aged Breast Carcinomas Patients | European Journal of Clinical Medicine
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology
![Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. | Semantic Scholar Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b8dc2360d630f1b27a065153037c5510f2a8abac/2-Table1-1.png)
Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. | Semantic Scholar
Syapse - A study in the Journal of Clinical Oncology concludes increasing access to germline genetic testing could expand clinicians' ability to apply precision treatments and personalize risk assessment for breast cancer
Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer | Journal of Clinical Oncology
![American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline - Runowicz - 2016 - CA: A Cancer Journal for Clinicians - Wiley Online Library American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline - Runowicz - 2016 - CA: A Cancer Journal for Clinicians - Wiley Online Library](https://acsjournals.onlinelibrary.wiley.com/cms/asset/b75cc8d1-336c-42c8-8cfc-0595b588a292/caac.v66.1.cover.jpg)